Breaking News

Financial Report: InterMune

February 22, 2013

Esbriet revenue up 204%

InterMune

4Q Revenues: $8.2 million (earnings were $2.7 million in 4Q11)

4Q Loss: $58.6 million (loss of $44.5 million in 4Q11)

FY Revenues: $26.2 million (earnings were $5.4 million FY11)

FY Loss: $150.1 million (loss of $154.8 million FY11)

Comments: Esbriet (pirfenidone) revenue in the quarter was $8.2 million, up 204%. Results in the quarter included the effect of the approximate 11% German price decrease of Esbriet, which became effective September 15, 2012. Esbriet was approved in Canada October 1, 2012 for the treatment of mild to moderate IPF and became commercially available on January 2, 2013.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks